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DOI 10.1016/j.ccr.2010.12.014SUMMARYIDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous
loss and gain of activities in the production of a-ketoglutarate (a-KG) and 2-hydroxyglutarate (2-HG), respec-
tively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple a-KG-dependent dioxygenases,
including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies
the same space as a-KG does in the active site of histone demethylases. Ectopic expression of tumor-
derived IDH1 and IDH2mutants inhibits histone demethylation and 5mChydroxylation. In glioma, IDH1muta-
tions are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC).
Hence, tumor-derived IDH1 and IDH2 mutations reduce a-KG and accumulate an a-KG antagonist, 2-HG,
leading to genome-wide histone and DNA methylation alterations.INTRODUCTION
The NADP+-dependent isocitrate dehydrogenase genes IDH1
and IDH2 are mutated in >75% of low grade gliomas and
secondary glioblastoma multiforme (GBM) and 20% of acute
myeloid leukemia (AML) (Mardis et al., 2009; Parsons et al.,
2008; Yan et al., 2009). IDH1 mutation has rapidly emerged asSignificance
IDH1 and IDH2 genes are mutated in >75% of low grade glio
20% of acute myeloid leukemia (AML). Two distinct alterati
IDH2: loss of its normal catalytic activity in the production of
produce 2-hydroxygulatrate (2-HG). We report here that 2-HG
genases, including histone demethylases, prolyl hydroxylases,
ylcytosine hydroxylases, and results in genome-wide changea reliable diagnostic and prognostic marker for identifying low
grade gliomas and for distinguishing secondary and primary
GBM (Ducray et al., 2009). In addition to the highly restricted
tumor spectrum, IDH1 and IDH2 mutations identified thus far
are heterozygous and produce single amino acid substitutions
either at arginine 132 (R132) in IDH1 or corresponding arginine
172 (R172) in IDH2 in glioma and leukemia, or at arginine 140mas and secondary glioblastoma multiforme (GBM) and in
ons are caused by the tumor-derived mutations in IDH1 or
a-ketoglutarate (a-KG) and gain of the catalytic activity to
is a competitive inhibitor of multiple a-KG-dependent dioxy-
collagen prolyl-4-hydroxylase, and the TET family of 5-meth-
of histone and DNA methylation.
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2-HG Is an Antagonist of a-KG(R140) in IDH2 in leukemia. Tumor-derived mutations targeting
R132 in IDH1 nearly completely abolish its normal catalytic
activity of oxidizing and decarboxylating isocitrate (ICT) to
produce a-KG, resulting in decreased a-KG and a-KG-depen-
dent prolyl hydroxylase (PHD) activity and leading to an increase
in a PHD substrate, HIF-1a (Zhao et al., 2009).
In addition to losing its normal catalytic activity, mutant IDH1
and IDH2 also gained the function of catalyzing the reduction
of a-KG to produce D-2-HG (also known as R-2-HG), resulting
in an accumulation of D-2-HG in IDH1 or IDH2 mutated gliomas
and AML (Dang et al., 2009; Gross et al., 2010;Ward et al., 2010).
In IDH1 mutated glioma, D-2-HG accumulated to astonishingly
high levels of 5–35 mmol/g of GBM (Dang et al., 2009), which
could be equivalent to 5–35 mM assuming the tissue density of
1 g/ml. Accumulation of a different enantiomer, L-2-HG (also
known as S-2-HG), has previously been linked to L-2-hydroxy-
glutaric aciduria (L-2HGA), a rare metabolic disorder that is
caused by a defect in L-2-HG dehydrogenase in mitochondria
and is associated with psychomotor retardation, progressive
ataxia and leukodystrophy (Rzem et al., 2004; Topcu et al.,
2004), and in a few cases increased risk of developing brain
tumors (Aghili et al., 2009). Although 2-HG has been proposed
to be an oncometabolite, its mechanism of action is not known.
2-HG and a-KG are structurally similar except that the oxygen
atom linked to C2 in a-KG is replaced by a hydroxyl group in
2-HG. This similarity suggests the possibility that 2-HG may
bind to and function as a competitive inhibitor of a-KG-depen-
dent dioxygenases. Mammalian cells express >60 dioxygenases
that utilize a-KG as a cosubstrate (Iyer et al., 2009; Loenarz and
Schofield, 2008), including the JmjC domain containing histone
demethylases (Tsukada et al., 2006) and recently discovered
TET family of 5-methylcytosine (5mC) hydroxylases that convert
5mC to 5-hydroxylmethycytosine (5hmC [Tahiliani et al., 2009]).
Many of these a-KG-dependent dioxygenases have a Km for
a-KG near physiological concentrations (Clifton et al., 2006;
Couture et al., 2007; Loenarz and Schofield, 2008; Simmons
et al., 2008), making their activities potentially susceptible to
fluctuation of a-KG and/or 2-HG. This study is directed toward
understanding how 2-HG functions as an oncometabolite and
determining the functional relationship between a-KG reduction
and 2-HG elevation.
RESULTS
2-HG Inhibits the Activity of a-KG-Dependent Histone
Demethylases In Vitro
To test the hypothesis that changes in concentrations of a-KG
and/or 2-HG may affect the activities of these dioxygenases,
we first examined in vitro effect of 2-HG on CeKDM7A,
a Caenorhabditis elegans dual specificity histone demethylase
that recognizes both dimethylated H3K9 and H3K27, using
synthetic methylated H3K9 and H3K27 peptides as substrates.
Mass spectrometric analysis demonstrated the removal of one
or two methyl groups from both peptides by CeKDM7A in an
a-KG-dependent manner (Figure 1A). Addition of 50 mM and
100 mM of D-2-HG resulted in partial and nearly complete inhi-
bition of CeKDM7A, respectively (Figure 1A). The same result
was obtained using D-2-HG synthesized from two distinct routes
(see Figures S1A and S1B available online), excluding the possi-18 Cancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc.bility that the observed inhibition was due to contamination in
D-2-HG. We also examined the effect of L-2-HG and found it
was more potent than D-2-HG in inhibiting CeKDM7A
(Figure 1A).
To further examine the mode of interaction between a-KG and
D-2-HG, we incubated CeKDM7A with a fixed concentration
(50mM) of D-2-HG and increasing amount of a-KG. A partial inhi-
bition of KDM7A toward both H3K9me2 and H3K27me2
peptides was observed in the presence of 50 mM D-2-HG and
100 mM a-KG. Addition of 300 mM a-KGwas capable of reversing
the inhibition of CeKDM7A by 50 mM D-2-HG (Figure 1B), indi-
cating that D-2-HG is a weak competitive inhibitor against
a-KG toward the CeKDM7A demethylase. The lower binding
affinity of 2-HG than a-KG is likely due to the hydroxyl moiety
being a weaker ligand of the catalytic Fe (II) center than the
keto group in a-KG.
We next determined the effect of 2-HG on human histone
H3K36 demethylase JHDM1A/KDM2A using nucleosomes as
a substrate. Consistent with the results from CeKDM7A, we
found that both enantiomers of 2-HG inhibited KDM2A with
D-2-HG being less potent than L-2-HG (Figure 1C; Figure S1C).
Moreover, increasing a-KG concentrations counteracted
D-2-HG inhibition on KDM2A (Figure 1D; Figure S1D).
To confirm the potency of both D- and L-2-HG in competing
with a-KG, we determined the inhibition constants (Ki) for
D-2-HG, L-2-HG, and N-oxalylglycine (N-OG), an a-KG analog
commonly used as a competitive inhibitor of dioxygenases
(Cunliffe et al., 1992; Epstein et al., 2001) toward KDM5B/
JARID1B/PLU-1, a H3K4 specific demethylase whose alter-
ations have been found in both prostate (Xiang et al., 2007)
and breast cancer (Lu et al., 1999; Yamane et al., 2007). These
experiments revealed that L-2-HG (Ki = 0.628 ± 0.036 mM) has
a similar potency as N-OG (Ki = 0.653 ± 0.128 mM) and is
17-fold more potent than D-2-HG (Ki = 10.87 ± 1.85 mM) in in-
hibiting KDM5B/JARID1B/PLU-1 (Figure S1E).
Together, these results demonstrate that both 2-HG enantio-
mers act asweak antagonists of a-KG to inhibit a-KG-dependent
histone demethylases with D-2-HG being significantly less
potent than L-2-HG.
2-HG Occupies the Same Space as a-KG Does
in the Active Site of CeKDM7A
To gain mechanistic insights of 2-HG inhibition, we determined
the structure of CeKDM7A bound with D-2-HG at 2.1 A˚ (Figure 2;
Table S1 and Figure S2). Like other JmjC-domain-containing
histone demethylase (Chen et al., 2006; Han et al., 2007), the
JmjC domain of the catalytic core of CeKDM7A also forms a jelly
roll motif with the Fe(II) coordinated by side chains of three highly
conserved residues (D497, H495, and H567) within the JmjC
domain (Figure 2A; Figure S2A). Notably, D-2-HG binds to the
catalytic core in close proximity of Fe (II). We also solved the
structure of CeKDM7A bound with a-KG at 2.25 A˚ (Figure 2B).
Comparison of these two structures reveals that D-2-HG adopts
a nearly identical orientation as a-KG with one notable
difference: whereas the Fe (II) is coordinated by two oxygen
atoms in the keto carboxyl end of a-KG, it is coordinated by
one oxygen atom and a hydroxyl group in D-2-HG (Figure 2C;
Figure S2B). These results provide a structural basis supporting
D-2-HG as a competitor of a-KG.
Figure 1. 2-HG Is a Competitive Inhibitor of a-KG for Histone Demethylases
(A) 2-HG inhibitsCaenorhabditis elegansKDM7A demethylase activity. CeKDM7A activities toward H3K9me2 andH3K27me2 peptides were assayed in the pres-
ence of increasing concentrations of either D-2-HG or L-2-HG as indicated. The demethylated products were analyzed by mass spectrometry (left) and mean
activity values of duplicated assays, represented by percentage of remaining methylated peptides (right), are shown. Error bars represent ± standard deviation
(SD) for triplicate experiments.
(B) a-KG rescues 2-HG inhibition of CeKDM7A demethylase activity. Error bars represent ± SD for triplicate experiments.
(C) 2-HG inhibits human JHDM1A/KDM2A demethylase activity. Purified recombinant JHDM1A demethylase activity was assayed in the presence of various
concentrations of D-2-HG and L-2-HG as indicated.
(D) a-KG reverses the inhibitory effect of D-2-HG on JHDM1A. JHDM1A activity was assayed in the presence of 50 mM D-2-HG and various concentrations
of a-KG.
See also Figure S1.
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Figure 2. 2-HG and a-KG Bind to the Same Site in Histone Demethy-
lases
(A) The structure of D-2-HG bound to CeKDM7A JmjC domain. D-2-HG and
CeKDM7A are shown in stick and cartoon representation, respectively.
Secondary structural elements of CeKDM7A are indicated. Fe (II) is colored
in black, Fe (II) coordination is represented by dotted lines and water molecule
is shown as orange ball.
(B) The structure of a-KG bound to CeKDM7A JmjC domain, illustrated as in
(A).
(C) Superimposition of structures shown in (A) and (B). See also Figure S2.
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Demethylases In Vivo
Inhibition of histone demethylases by 2-HG in vitro and binding
of 2-HG and a-KG to the same site in the catalytic center of
CeKDM7A led us to determine the effect of 2-HG on genome
wide histone methylation in vivo. To this end, we synthesized
cell-permeable a-KG and racemic octyl-2-HG and verified their
structures by NMR (Figures S3A–S3D). Addition of 10 mM
octyl-2-HG to the cultured U-87MG cells resulted in a significant
accumulation of intracellular 2-HG as determined by GC-MS
assay (Figure S3E) and increase of dimethylation on H3K9
and H3K79 by 5- and 10-fold, respectively (Figure 3A; Fig-
ure S3F). Addition of cell-permeable octyl-a-KG reversed the
increase of both H3K9 and H3K79 dimethylation, providing
in vivo evidence supporting the competitive interaction
between 2-HG and a-KG. We also synthesized enantiomer
specific cell-permeable 2-HG and compared their inhibitory
potency. Consistent with in vitro assay, treatment of U-87MG
cells with either cell-permeable D- or L-2-HG increased dime-
thylation on both H3K9 and H3K79 with octyl-D-2-HG being
less potent than octyl-L-2-HG (Figures 3B and 3C; Figures
S3G and S3H).
R132H Mutation of IDH1 Alters Histone Methylation
in Human Glioma Cells and Tumor Samples
We next ectopically expressed IDH1R132H in U-87MG cells and
determined the levels of multiple histone methylation markers.
Comparing with cells expressing empty vector, the ectopic
expression of wild-type increased a-KG by 20% in U-87MG
cells, ectopic expression of IDH1R132H mutant resulted in
a near 60% reduction of a-KG by 60% and <20-fold increase
in D-2-HG (Figure S3I). A visible increase in H3K4 monomethyla-
tion, H3K27 dimethylation, H3K4 trimethylation, H3K9 dimethy-
lation, and H3K79 dimethylation was observed (Figure 3D;
Figure S3J). Addition of cell-permeable octyl-a-KG restored
histone demethylation. Together, these results indicate that in
addition to CeKDM7A and KDM2A, 2-HG and mutant IDH1
inhibit wide range of histone demethylases, including those
involved in the demethylation of H3K4, H3K9, H3K27, and
H3K79, and both inhibitions by 2-HG and IDH1 mutant can be
reversed by the addition of cell-permeable a-KG.
These results led us to determine whether IDH1 mutation
could affect histone methylation in primary tumors. We
analyzed H3K79 dimethylation in a panel of 20 human glioma
samples, 10 containing wild-type IDH1 and 10 bearing mutated
IDH1 (R132H) (see Table S2). H3K79 dimethylation levels were
found to be significantly elevated in glioma samples that harbor
IDH1 mutation compared to tumor samples that are similar
grade but have wild-type IDH1 (Figure 3E; Figure S3K). To
further substantiate this result, we determined the expression
of several HOXA genes whose increased expression is associ-
ated with increased H3K79 dimethylation in MLL-rearranged
mouse leukemia and human AML patients (Krivtsov et al.,
2008). qRT-PCR analysis demonstrated that the expression
of these HOXA genes was increased in cells with forced
expression of the IDH1R132H (Figure 3F). Collectively, these
results demonstrate that either expression of mutant IDH1 or
increase of 2-HG results in an inhibition of histone demethy-
lases in vivo.
Figure 3. Reduced Activity of IDH1 and Elevated 2-HG Increase Genome-Wide Histone Methylations and Alter Gene Expression
(A–C) Cell-permeable octyl-2-HG increases histone methylation. H3K9me2 and H3K79me2 levels of U-87MG cells treated with racemic octyl-2-HG (A), octyl-D-
2-HG (B), and octyl- L-2-HG (C) were analyzed by western blotting.
(D) Histonemethylation increased by IDH1R132H overexpression can be rescued by addition of cell-permeable octyl-a-KG. Specified histonemethylation levels of
U-87MG cells expressing IDH1R132H were analyzed by western blotting.
(E) ElevatedH3K79 dimethylation in IDH1R132H gliomas. IDH1wild-type or heterozygous for R132H glioma samples were subjected to IHC analysis for H3K79me2
methylation. Scale bars represent 50 mm. Shown are representative IHC results (left) and mean values of IHC quantification (right). Error bars represent ± SD for
triplicate experiments. Complete results of all 20 samples are presented in Figure S3K.
(F) Reduction of IDH1 activity activates HOXA genes. HOXA mRNA levels were analyzed by qRT-PCR in U-87MG cells after forced expression of wild-type or
R132H mutant IDH1. Error bars represent ± SD for triplicate experiments. See also Figure S3.
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Demethylases
Given the previous observations that mutations in IDH1 or IDH2
cause both a-KG reduction and 2-HG accumulation and the
current finding that 2-HG acts as an antagonist of a-KG in vitro,
we sought to determine whether reducing the activity of IDH1
and IDH2 could cause similar increase in histone methylation.
To this end,we treatedcellswithoxalomalate, acompetitive inhib-
itor of IDH1 and IDH2 that would decrease both cytoplasmic and
mitochondrial a-KG. We found that this treatment led to a dose-
dependent increase of trimethylation of H3K4, dimethylation at
H3K9, H3K27, andH3K79, and amodest increase in H3K4mono-methylation (Figure 4A; Figure S4). The differences between
different histone demethylases in their responses to oxalomalate
treatment probably reflect their different affinities toward a-KG.
To further support the above observation, we also determined
the expression of the same panel of HOXA genes (see Figure 3F)
and found that expression of these HOXA genes was increased
in cells treated with oxalomalate (Figure 4B) as well as in cells
depleted for IDH1 by shRNA knockdown (Figure 4C). Similar
conclusion was also obtained with two additional a-KG-depen-
dent dioxygenases (see below). As both oxalomalate treatment
and IDH1 knockdown reduced a-KGwithout 2-HG accumulation,
these results indicate that inhibition of IDH1 could cause similarCancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc. 21
Figure 4. INHIBITION of IDH1 Reduces Histone Demethylase Activ-
ities In Vivo
(A) Inhibition of IDH1 activity increases histone methylation. Specified histone
methylation levels in U-87MG cells treated with increasing concentrations of
oxalomalate were analyzed by western blotting.
(B and C) Reduction of IDH1 activity activates HOXA genes. HOXA mRNA
levels were analyzed by qRT-PCR in U-87MG cells after knocking down
IDH1 (C), and treatment of oxalomalate (B). Error bars represent ± SD for trip-
licate experiments. See also Figure S4.
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ing a competitive mode between a-KG and 2-HG.a-KG-dependent prolyl hydroxylases and collagen
prolyl-4-hydroxylases are inhibited by reduced IDH1
activity or R132H
In addition to histone demethylases, mammalian cells express
a large number of dioxygenases that also utilize a-KG as a key22 Cancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc.substrate (Iyer et al., 2009; Loenarz and Schofield, 2008). To
determine how broadly IDH1 mutations affect a-KG-dependent
dioxygenases, we investigated the effect of reduced IDH1
activity and increased 2-HG on two additional a-KG-dependent
dioxygenases; prolyl hydroxylases (PHDs) and collagen prolyl-4-
hydroxylase (C-P4H).
Wefirstdetermined theeffectof reduced functionof IDH1on the
levels of HIF-1a and endostatin. HIF-1a is a transcription factor
whose function is linked to metabolism, angiogenesis and tumor-
igenesis, and whose protein level is downregulated under
normoxic conditions by PHD-mediated hydroxylation and subse-
quent hydroxylation-targeted ubiquitination (Bruick and
McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001; Jaakkola
et al., 2001). Endostatin is a 20-kDa secretory peptide
implicated in inhibiting angiogenesis and tumor growth and its
production is catalyzed by C-P4H (Krane, 2008; O’Reilly et al.,
1997). We found that knocking down IDH1 by shRNA increased
HIF-1a and decreased endostatin (Figure 5A). Likewise, inhibition
of endogenous IDH1byoxalomalate treatment similarly increased
HIF-1a and decreased endostatin (Figure 5B). Conversely,
ectopic expression of wild-type IDH1 decreased HIF-1a and
increased endostatin (Figure 5C). In addition to PHDs, the stability
and steady-state levels of HIF-1a protein are also regulated by
FIH-1 (factor inhibiting HIF-1a) (Lando et al., 2002; Mahon et al.,
2001), an asparaginyl hydrogenase whose activity is dependent
on a-KG and could therefore also be affected by reduced function
of IDH1. Unlike knocking down PHD2 that caused an evident
increase of HIF-1a, knocking down FIH-1 in 293T cells did not
appreciably affect the steady-state level of HIF-1a (Figure S5A).
This result indicates that, at least in 293T cells, FIH-1 does not
appear to play a major role in HIF-1a degradation, a notion that
is consistent with a recent study in Fih-1 deletion mice showing
that FIH-1 plays little or no discernible role in altering HIF stability
and function (Zhang et al., 2010). We therefore conclude that the
increase of HIF-1a in cells with reduced function of IDH1 is largely
caused by the impairment of PHDs.
To determine how tumor-derived IDH1 mutants affect these
two dioxygenases, we ectopically expressed IDH1R132H in
U-87MGcells and determined the steady-state levels of both en-
dostatin and HIF-1a proteins. We observed a dose-dependent
increase of HIF-1a and decrease of endostatin with increasing
expression of IDH1R132H (Figures 5D and 5E). Ectopic expression
of IDH1R132H did not significantly affect the levels of collagen
XVIII mRNA (Figure S5B), supporting the notion that decreased
endostatin protein on IDH1R132H expression is due to inhibition
of C-P4H. An evident endostatin decrease and HIF-1a increase
were seen in cells in which IDH1R132H is expressed at a level
similar to that of endogenous wild-type IDH1 (lane 2, Figure 5E),
excluding the possibility that observed changes in the activity of
both PHDs and C-P4H dioxygenases are caused by the grossly
overexpression of IDH1 mutant.
We also performed immunohistochemical staining of endosta-
tin in the same panel of 10 IDH1 wild-type and 10 IDH1mutated
gliomas (Table S2). We found that tumors with the R132H muta-
tion expressed significantly less endostatin than those contain-
ing wild-type IDH1 (Figure 5F; Figure S5C). Together, these
results demonstrate that the activities of a-KG-dependent
PHDs and C-P4H are supported by the function of IDH1 and
impaired by tumor-derived mutant IDH1.
Figure 5. IDH1 Function Supports the Activity of a-KG-Dependent Dioxygenases In Vivo
(A–E) The effects of reducing or increasing IDH1 function on two a-KG-dependent dioxygenases, PHDs and C-P4H, were examined in U-87MG cells after knock-
down IDH1 (A), treatment of oxalomalate, a competitive inhibitor of IDH1 (B), overexpression of wild-type IDH1 (C), and tumor-derived IDH1R132Hmutant (D and E).
The protein levels of HIF-1a, endostatin, and ectopically and endogenously expressed IDH1 were determined by western blotting.
(F) Decreased endostatin in IDH1R132H gliomas. IDH1wild-type or heterozygous for R132H glioma samples were subjected to IHC analysis for endostatin. Shown
are representative IHC results (left) andmean values of IHC quantification (right). Scale bars represent 50 mm. Error bars represent ± SD for triplicate experiments.
Complete results of all 20 samples are presented in Figure S5C. See also Figure S5.
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We next examined more directly the effect of 2-HG on these two
dioxygenases in cells. Treatment of U-87MG cells with either
cell-permeable racemic mixture or enantiomer-specific 2-HG
increased HIF-1a and decreased endostatin (Figures 6A–6C).
Similar increase of HIF-1a was also observed in 293T cells
treated with octyl-D-2-HG (Figure S6A). Consistent with the inhi-
bition of histone demethylases, octyl-D-2-HG exhibited less
potent inhibition on both dioxygenases than octyl-L-2-HG and
addition of cell-permeable octyl-a-KG substantially suppressed
the effect of 2-HG.
Consistent with the hypothesis that the effect of 2-HG in stabi-
lizing HIF-1a protein in vivo is achieved by antagonizing the
binding of a-KG to PHD2, treatment of cells with a cell-perme-
able NOG, dimethyloxalylglycine (DMOG), or knocking down
PHD2 both resulted in an accumulation of HIF-1a protein and
activation of several HIF-1a target genes (Figures 6D and 6E;
Figures S6B–S6E), but treatment of cells with the combination
of cell-permeable octyl-D-2-HG and either DMOG or siPHD2
did not cause a further increase of HIF-1a. Treatment of cellswith CoCl2, a mimetic of hypoxia and a chemical inducer of
HIF-1a, accumulated HIF-1a to a level significantly higher than
either DMOG or siPHD2 treatment, excluding the possibility
that the lack of further HIF-1a accumulation by the octyl D-2-
HG in DMOG- or siPHD2-treated cells is because that HIF-1a
has already accumulated to the maximal level by DMOG or
siPHD2 treatment. Further supporting the notion that 2-HG
induces HIF-1a through an inhibition of PHD2 by competing off
a-KG, addition of octyl-2-HG to hypoxic cells in which the
activity of PHD is reduced by the decrease cosubstrate oxygen,
but not impaired a-KG binding, resulted in further HIF-1a accu-
mulation (Figure 6F).
Ectopic Expression of Tumor-Derived IDH1 and IDH2
Mutants Reduces TET-Catalyzed 5hmC Production
Very recently, a class of a-KG-dependent dioxygenase, the TET
family of proteins, was discovered that catalyze the conversion
of 5-methylcytosine (5mC) to 5-hydroxylmethycytosine (5hmC)
(Iyer et al., 2009; Tahiliani et al., 2009). Mammalian cells express
three TET genes, TET1, TET2, and TET3. Although the foundingCancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc. 23
Figure 6. 2-HG Inhibits the Activity of a-KG-
Dependent Dioxygenases In Vivo
(A–C) Cell-permeable 2-HG increases HIF-1a and
decreases endostatin. U-87MG cells were treated
with racemic octyl-2-HG (A), octyl-L-2-HG (B), and
octyl-D-2-HG (C). The steady state levels of endo-
statin and HIF-1a proteins were determined by
direct western blotting.
(D) DMOG treatment abolishes 2-HG effect on
HIF-1a induction.
(E) PHD2 knock down abolishes 2-HG effect on
HIF-1a induction.
(F) 2-HG treatment further induces HIF-1a in
hypoxic U-87MG cells. See also Figure S6.
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mixed-lineage leukemia (MLL) in chromosomal ten-eleven-
translocation in rare cases of AML and suspected to be an onco-
gene (Lorsbach et al., 2003; Ono et al., 2002), it was recently
discovered that TET2 is mutationally inactivated in 15% of
myeloid cancers, including 22% of AML (Delhommeau et al.,
2009; Langemeijer et al., 2009). Given the dependence of TET
catalytic activity on a-KG, we set forth to determine whether
IDH1 and IDH2 mutations and D-2-HG would affect TET activi-
ties and DNA cytosine hydroxymethylation and methylation.
The level of 5hmC in most cells is very low, but is substantially
increased in cells transiently transfected with plasmids express-
ing the wild-type catalytic domain of TET (TET1-CD and TET2-
CD) protein that can be readily detected by immunofluores-
cence using an antibody specifically recognizing 5hmC (Ito
et al., 2010; Tahiliani et al., 2009) (Figure 7A). Immunofluores-
cence with the anti-5hmC antibody revealed that coexpression
of wild-type IDH1with TET1-CD or TET2-CD caused a significant
increase of 5hmC signal (Figure 7A), suggesting that the concen-
tration of a-KG is a rate-limiting factor of TET2 catalyzed hydrox-
ylation of 5-methylcytosine in TET1-overexpressing cells.
Notably, cotransfection of TET1-CD or TET2-CD with IDH1R132H
reduced the 5hmC signal to a barely detectable low level.
Essentially the same result was also obtained for IDH2. Both
TET1- and TET2-catalyzed 5mC-to-5hmC conversions were
substantially increased by the coexpression with wild-type
IDH2, but nearly completely inhibited by the coexpression of
either IDH2R140Q or IDH2R172K mutants (Figures S7A and S7B).
Together, these results demonstrate an inhibitory effect of
mutant IDH1 and IDH2 toward the hydroxylase activity of the
TET family proteins.24 Cancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc.c
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nomic DNA from HEK293T cells tran-
siently transfected with TET1 or TET2
individually or in combination with either
wild-type or mutant IDH1 and IDH2, and
determined 5hmC levels by dot-blot that
allowed for more quantitative measure-
ment than the immunofluorescence.
These experiments demonstrate that
ectopic expression of the wild-type, but
not the mutant of TET1 or TET2, resulted
in high levels of 5hmC in the cells
comparing with cells transfected withontrol vector (Figures 7B and 7C). Coexpression with wild-
pe IDH1 or IDH2 caused a significant increase of 5hmC. For
xample, in the assays using 50 ng genomic DNA, TET2-cata-
zed 5hmC production was increased by 149% and 166% by
e coexpression of wild-type IDH1 or IDH2, respectively. In
ontrast, coexpression of TET2-CD with three tumor-derived
utants all caused a substantial decrease of TET2-mediated
hmC production, resulting in a 70% reduction of 5hmC by the
oexpression of IDH1R132H, 66% reduction by both IDH2R140Q
nd IDH2R172K (Figure 7B; Figure S7C). Virtually the same result
as also obtained for TET1-catalyzed 5hmCproduction that was
creased by 222% and 203% by the coexpression of wild-type
H1 or IDH2, respectively, but reduced by 60%, 69%, and 68%
y the coexpression of IDH1R132H, IDH2R140Q, and IDH2R172K,
spectively (Figure 7C; Figures S7D and S7E).
-HG Inhibits the Activity of TET 5-Methylcytosine
ydroxylases
e next tested whether 2-HG may function as an inhibitor of
-KG-dependent TET hydroxylases. We carried out in vitro enzy-
atic assay to test this possibility using purified Flag-tagged
ouseTETcatalyticdomainsaswell as their correspondingcata-
tic mutants following previous published procedure (Ito et al.,
010). Omission of a-KG completely abolished the activity of
ET in catalyzing the conversion of 5mC to 5hmC, confirming
e dependence of TET activity on a-KG (Figures 8A and 8B). In
e presence of 0.1 mM of a-KG, addition of 10 mM D-2-HG re-
ulted in a partial (33%) inhibition of TET2 and addition of
0 mM D-2-HG resulted in more inhibition (83%) of TET2 (Fig-
re 8A). D-2-HG exhibited a less pronounced inhibitory effect
ward TET1, reducing the 5hmC production by 28% and 47%,
Figure 7. Tumor-Derived IDH1 and IDH2 Mutants Inhibit the 5hmC Production by TET1 and TET2
(A) HEK293 cells were transiently transfected with plasmids expressing indicated proteins. Thirty-six to forty hours after the transfection, cells were fixed and
stained with antibodies specific to Flag to determine the expression of TET protein, to 5hmC to determine the levels of 5hmC, and to DAPI to view the cell nuclei
or visualized for green fluorescence to determine the expression of IDH1 proteins. Scale bars represent 50 mm. Additional results on the inhibition of TET1 and
TET2 function by IDH2 mutants are presented in Figures S7A and S7B.
(B and C) HEK293 cells were transiently transfected as described in (A). Thirty-six to forty hours after the transfection, genomic DNAs were isolated from the
transfected cells, spotted on nitrocellulose membranes and immunoblotted with an antibody specific to 5hmC. Quantification of 5hmCwas calculated from three
independent assays. The expression of individual proteins was determined by immunoblotting as shown in the right. One representative quantification of 5hmC
level determined from the assays using 50 ng genomic DNA is included and the rest of the quantifications are presented in Figures S7C–S7E. Error bars
represent ± SD for triplicate experiments. See also Figure S7.
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Figure 8. Glioma Harboring Mutant IDH1 Have Decreased 5hmC
(A and B) Recombinant catalytic domains and corresponding catalytic mutants of murine TET2 (A) or TET1 (B) protein was produced and purified from insect Sf9
cells, and incubated with double-stranded DNA oligonucleotides containing a fully methylated MspI site in the presence of Fe (II) and a-KG (0.1 mM). Recovered
oligonucleotides were digested withMspI, end labeled with T4DNA kinase, digestedwith DNaseI and phosphodiesterase, and analyzed by TLC. Error bars repre-
sent ± SD for triplicate experiments.
(C) IDH1 wild-type or heterozygous for R132H glioma samples were subjected to IHC analysis for 5hmC. Shown are representative IHC results (left) and mean
values of IHC quantification (right). Scale bars represent 50 mm. Error bars represent ± SD for triplicate experiments. Complete results of all 20 samples are
presented in Figure S8A.
(D) IDH1 wild-type or heterozygous for R132H glioma samples were subjected to IHC analysis for 5mC. Scale bars represent 50 mm. Shown are representative
IHC results (left) and mean values of IHC quantification (right). Error bars represent ± SD for triplicate experiments. Complete results of all 20 samples are
presented in Figure S8B.
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reaction (Figure 8B). These results indicate that D-2-HG is
aweak inhibitor of TEThydroxylases.Wealsoexamined theeffect
of L-2-HG and found it wasmore potent thanD-2-HG in inhibiting
both TET2 and TET1 with 10 mM L-2-HG capable of inhibiting
most of TET1 and TET2 activity in the presence of 0.1 mM a-KG.
In normal mouse brain, 5hmC constitutes a surprisingly high
level of total nucleotides in many different cell types, ranging
from 0.2% in granule cells to 0.6% in Purkinje cells (Kriaucionis
and Heintz, 2009; Munzel et al., 2010). It is currently not clear
the scope and level of 5hmC in primary tumors. We analyzed
5hmC by immunohistochemistry (IHC) in the same panel of26 Cancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc.20 human glioma samples (Table S2). Notably, 5hmCwas readily
detectable by IHC in all glioma samples we have examined
regardless of their IDH1 status. Glioma samples harboring
a mutant IDH1, however, accumulate significantly lower 5hmC
than those containingwild-type IDH1. The average relative inten-
sity of 5hmC was 8.04 ± 3.97 in glioma with wild-type IDH1 and
reduced to and 4.27 ± 1.62 (p = 0.013) in IDH1-mutated gliomas
(Figure 8C; Figure S8A). This result provides in vivo evidence in
human tumor supporting the conclusion that IDH1 mutations
reduce the levels of 5hmC.
Promoter DNA methylation profiling analysis has recently
revealed that a subset of glioblastoma, proneural subgroup
Cancer Cell
2-HG Is an Antagonist of a-KGpreviously identified by gene expression profiling and exhibiting
features of increased PDGRF gene expression and IDH1 muta-
tion (Verhaak et al., 2010), displays hypermethylation at a large
number of loci (Noushmehr et al., 2010), suggesting a potential
link between IDH1 mutation and increased DNA methylation.
Given that TET-catalyzed 5hmC production from 5mC, we there-
fore determined 5mC by immunohistochemistry in the same
panel of 20 human glioma samples. In contrast to 5hmC levels,
gliomas with IDH1 mutations accumulate significantly higher
5mC than those containing wild-type IDH1. The average relative
intensity of 5mC was 3.75 ± 1.49 in glioma with wild-type and
increased to 6.33 ± 3.02 (p = 0.017) in gliomas harboring amutant
IDH1 (Figure 8D; Figure S8B). This result provides in vivo
evidence in human tumor that IDH1 mutations reduce the levels
of 5hmC with an associated increase of 5mC.
DISCUSSION
D-2-HG Is a Weak Antagonist of a-KG
In this study, we provide evidence that D-2-HG is an antagonist
of a-KG and inhibits multiple a-KG-dependent dioxygenases.
Notably, both enantiomers of 2-HG, especially D-2-HG that
accumulated in IDH1 and IDH2 mutated tumors, are weak
inhibitors in competing with a-KG. In the presence of 0.1 mM
a-KG, 10mMD-2-HG exhibits a clear, but only a partial inhibitory
effect toward KDM7A histone demethylase and TET methylcyto-
sine hydroxylases. In other words, as much as 100-fold molar
excess of D-2-HG over a-KG is needed to cause a significant
inhibitory effect toward a-KG-dependent dioxygenases. This
weak activity may be explained by the fact that the hydroxyl
moiety in D-2-HG is a weaker ligand of the catalytic Fe (II) center
than the keto group in a-KG. We argue that the requirement for
such a high concentration of D-2-HG to inhibit this class of
enzymes, although seemingly supraphysiological, is pathophy-
siologically relevant to 2-HG-mediated tumorigenesis. IDH1-
mutated gliomas accumulated D-2-HG to a very high level,
between 5–35 mmol/g with an average of 15.48 mmol/g (Dang
et al., 2009). The concentrations of a-KG in the same cohort of
IDH1-mutated glioma are between 0.016 to 0.085 mmol/g with
an average of 0.0415 mmol/g indicating that the ratio of D-2-
HG and a-KG would reach an average of 373-fold. Our findings
therefore support the notion that although D-2-HG may not play
a significant role in the regulation of a-KG-dependent di-
oxygenases in normal cells because of its low level, it could
play an important role under pathological conditions in tumor
cells expressing mutated IDH1 or IDH2. The weak activity of
D-2-HG also helps to explain why tumor cells need to accumu-
late and can tolerate such a high level of D-2-HG.
Does Reduced a-KG Sensitize a-KG-Dependent
Enzymes to the Inhibition by 2-HG?
Joining the loss-of-function mutations targeting fumarate hydra-
tase (FH) and different subunits of succinate dehydrogenase
(SDH) (Baysal et al., 2000; Tomlinson et al., 2002), the discovery
of IDH1 and IDH2mutations in human cancers further highlights
the direct link between metabolic dysregulation and tumorigen-
esis. Mutations targeting FH and SDH lead to similar increase in
the PHD substrate, HIF-1a (Isaacs et al., 2005; Pollard et al.,
2005; Selak et al., 2005). Furthermore, succinate, the substrateof SDH that is accumulated in cells with reduced or inactivation
of SDH, has been shown to directly inhibit multiple a-KG-depen-
dent enzymes, including histone demethylases (Smith et al.,
2007). Thus, a common feature of the mutations in these three
metabolic enzymes is the reduced activity of a-KG-dependent
dioxygenases, either indirectly by the accumulation of competi-
tive inhibitors, namely fumarate, succinate, and 2-HG, or directly
through the reduction of IDH1 and IDH2 catalytic activity in a-KG
production. It will be interesting to determine whether histone
and DNA methylations are similarly altered in SDH and FH
mutated tumor cells.
We previously showed that mutant IDH1 retains its ability to
associate with wild-type subunit and forms a catalytic inactive
heterodimer, leading to the dominant inhibition of wild-type
IDH1 (Zhao et al., 2009). This model is supported by the recent
crystal structural analysis of wild-type:mutant IDH1 heterodimer
showing that the R132H mutation hinders the conformational
changes from the initial ICT-binding state to the pretransition
state (Yang et al., 2010). In other words, the IDH1 enzyme activity
in IDH1-mutated tumor cells is reduced to25% of normal cells.
Production of D-2-HG by the mutant IDH1 and IDH2 homo-
dimers raises a question of relative contribution of a-KG reduc-
tion and D-2-HG accumulation to tumorigenesis. We showed
here that treatment of cells with either 2-HG enantiomer or inhi-
bition of IDH1 and/or IDH2 activity alone in the absence of
D-2-HG accumulation causes similar effects of reducing the
activity of multiple a-KG-dependent dioxygenases. It is possible
that IDH1 or IDH2mutations alone do not reduce cellular level of
a-KG sufficiently low to have a significant tumorigenic conse-
quence, but nonetheless sensitize a-KG-dependent dioxyge-
nases to the inhibitory effect by the large amounts of 2-HG accu-
mulated in the cell. Hence, a-KG reduction and D-2-HG
accumulation cooperatively contribute to tumorigenesis. The
findings that a cell-permeable a-KG derivative can reverse the
effects of 2-HG inhibition and that D-2-HG is a weak competitive
inhibitor suggest that drugsmimicking a-KGmerit exploration as
a therapy for tumors that harbor an IDH1 or IDH2mutation, either
alone or in combination with inhibitors targetingmutant IDH1 and
IDH2 to reduce the 2-HG production.
IDH1 and IDH2 Mutations Alter Histone and DNA
Methylation
Notable among the a-KG-dependent dioxygenases whose
activities are reduced by IDH1 and IDH2mutations are the fami-
lies of histone demethylases and TET 5-methylcytosine hydrox-
ylases, leading to genome-wide increase and decrease of
histone methylation and 5-hydroxymethylcytosine, respectively.
We demonstrate that both histone demethylases and TET
hydroxylases are inhibited by D-2-HG. The exact function of
hydroxylation of 5-methylcytosine, whether representing
a distinct transcriptional regulation or an intermediate of DNAde-
methylation, is currently unclear but has been speculated to play
a role in epigenetic control. In the case of histone demethylases,
multiple histone modification markers are affected. Recently, it
was reported that expression of IDH1R132H suppresses TET2
activity and the mutations of IDH1 and IDH2 genes occur in
a mutual exclusive manner with that of TET2 gene in AML (Fig-
ueroa et al., 2010). Our finding that expression of mutants
IDH1 or IDH2 andD-2-HG inhibit the activity of TET2 in catalyzingCancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc. 27
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biochemical basis for the mutual exclusivity of IDH1/2 and
TET2 gene mutations. Together with the previous finding that
IDH1-mutated gliomas display hypermethylation at a large
number of loci (Noushmehr et al., 2010), these findings suggest
that instead of altering the expression of a single or a few specific
genes, mutations in IDH1 and IDH2 may change the expression
of potentially large number of genes. Given that both mutations
of IDH1 and TET2 have been reported to occur at a very early
stage during glioma and leukemia development (Delhommeau
et al., 2009; Langemeijer et al., 2009; Watanabe et al., 2009),
alteration of histone and DNA methylations resulting from IDH1
and IDH2 mutations may contribute to tumorigenesis through
altering epigenetic control and potentially the fates of stem or
progenitor cells.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, Western Blotting, and Chemical
Treatments
Procedures for cell culture, transfection, and western blotting are described in
the Supplemental Experimental Procedures. Treatments of cells with cell-
permeable a-KG or 2-HG were carried out by adding the octyl-a-KG ester or
octyl-2-HG ester to the culture medium to a final concentration 4–6 hr before
harvesting as indicated. Dimethyloxalylglycine (DMOG; Frontier Scientific)
treatments were carried out by adding DMOG to the culture medium to a final
concentration of 1 mM, 6 hr before harvesting. When both DMOG and octyl-2-
HG were used for cell treatment, DMOG (1 mM final concentration) was added
to the medium 2 hr before the addition of octyl-2-HG (10 mM final concentra-
tion), and cells were harvested 4 hr after octyl-2-HG was added. CoCl2 treat-
ments were carried out by adding CoCl2 to the medium to a final concentration
of 200 mM, 6 hr before harvesting.
Crystallography Study
Purification and crystallization of His-tagged CeKDM7A were described in
Supplemental Experimental Procedures. Data sets were collected on beam-
line BL17U at Shanghai Synchrotron Radiation Facility (SSRF). All data were
processed using the program HKL2000. The crystals of CeKDM7A in complex
with D-2-HG contain two molecules in one asymmetric unit. The structures of
CeKDM7A with D-2-HG or a-KG were determined by molecular replacement
method using CeKDM7A structure and the models were manually built with
COOT. All refinements were performed using the refinement module
phenix.refine of PHENIX package. The model quality was checked with the
PROCHECK program, which showed good stereochemistry according to the
Ramachandran plot for all structures. The structure superimposition was per-
formed with COOT. All structure figures were generated by PyMol.
Enzymatic Assays
To assay human JHDM1A/KDM2A demethylase activity toward H3K36me2,
His tagged JHDM1A was first obtained by transforming pET28a-JHDM1A
into Escherichia coli BL21 and protein expression was induced by addition
of 1 mM IPTG at 30C when cell density reaches 0.5 OD600 units. Cells were
lysed by sonication and Ni-NTA agarose was used to purify His-JHDM1A
fusion proteins. Histone demethylase assay was carried out by incubating
2 mg oligonucleosomes, 4 mg purified His-JHDM1A, and/or 10–50 mM L- or
D-2-HG in histone demethylation buffer [50 mM HEPES (pH 8.0), 625 mM
Fe(NH4)2(SO4)2, 0.1–0.5 mM a-KG, 2 mM ascorbate] at 37
C for 2–3 hr and
the reactions were stopped by the addition of SDS loading buffer and subse-
quently analyzed by western blotting using anti-H3K36me2 antibody.
To measure CeKDM7A demethylase activity toward H3K9me2 and
H3K27me2, two synthetic dimethylated peptides H3K9me2 [ARTKQTARK
(me2)STGGKA] and H3K27me2 [QLATKAARK (me2)SAPAS] were used as
substrates. Demethylase assays were carried out in the presence of 10 mg
enzyme, 1 mg peptide in 20 ml buffer 20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
50 mM (NH4)2Fe(SO4)2, 100 mM a-KG, 2 mM Vc, 10 mM PMSF for 3 hr. The de-28 Cancer Cell 19, 17–30, January 18, 2011 ª2011 Elsevier Inc.methylation reaction mixture was desalted by passing through a C18 ZipTip
(Millipore). To examine the inhibitory effect of 2-HG, various concentrations
of 2-HG were incubated with KDM7A briefly before adding other reaction
mixtures. The samples were analyzed by a MALDI-TOF/TOF mass
spectrometer.
Three different assays were performed for TET-catalyzed 5mC-to-5hmC
conversion. For in vivo assay using immunofluorescence, plasmids expressing
Flag tagged TET proteins were either singularly transfected or cotransfected
with plasmid expressing GFP-IDH fusion protein to HEK293T cell. Thirty-six
to forty hours after transfection, cells were fixed with 4% paraformaldehyde
in PBS for 15 min and then washed with cold PBS. Cells were permeabilized
with 0.4% Triton X-100 in PBS for 15 min. For 5mC and 5hmC staining, DNA
was denatured with 2 N HCl for 30 min. and then neutralized with 100 mM
Tris-HCl (pH 8.5) for 10 min. After washing three times with PBS, samples
were blocked for 1 hr with 5% goat serum, 1% BSA 0.05% Tween20 in
PBS. The primary antibodies were added and incubated at 4Covernight. After
washing three times with PBS, cells were incubated with secondary antibodies
and DAPI for 30 min, followed by triple wash with PBS. Images were recorded
using Olympus immunofluorescence microscope DP71 and Olympus soft-
ware. Antibodies to FLAG (Sigma-Aldrich, diluted at 1:1000), 5-hydroxyme-
thylcytosine (Active Motif, Carlsbad, CA, dilution at 1:4000), 5-methylcytosine
(clone 162 33 D3, Calbiochem, San Diego, CA, diluted at 1:5001000) were
purchased commercially.
For dot-blot assays, we followed the procedures described previously
(Ito et al., 2010). Briefly, genomic DNA was spotted on nitrocellulose
membranes. The membrane was baked at 80C and then blocked with 5%
skimmed milk in TBST for 1 hr, followed by the incubation with the anti-
5hmC antibody overnight at 4C and HRP-conjugated anti-rabbit IgG
secondary antibody for 1 hr at room temperature. After washing three times
with TBST, the membrane was treated with ECL and scanned by a Typhoon
scanner. The quantification of dot-blot was done by Image-Quanta software
(GE Healthcare).
In vitro TET-catalyzed 5mC-to-5hmC conversion was assayed as described
previously (Ito et al., 2010) and described in detail in the Supplemental Exper-
imental Procedures. Briefly, 5 mg purified proteins were incubated with 0.5 mg
double-stranded oligonucleotide substrates in 50 mM HEPES (pH 8), 75 mM
Fe(NH4)2(SO4)2, 2 mM ascorbate, and 0.1 mM a-KG with or without a various
amount of 2-HG for 3 hr at 37C. Oligonucleotide substrates were purified and
then digestedwithMspI. 50-end of the digested DNAwas treatedwith calf alka-
line phosphatase and labeled with [g-32P]ATP and T4 polynucleotide kinase.
Labeled fragments were ethanol-precipitated and digested with 10 mg of
DNase I and 10 mg Phosphodiesterase I in the presence of 15 mM MgCl2,
2 mM CaCl2 at 37
C. One microliter digestion product was spotted on
a PEI-cellulose TLC plate (Merck) and separated in an isobutyric acid/water/
ammonium hydroxide (66:20:2) running buffer.
Clinic Samples, Immunohistochemistry, and Histopathological
Analyses
All glioma samples were acquired from Affiliated Huashan Hospital of Fudan
University. A physician or nurse practitioner obtained informed consent from
the patients. The procedures related to human subjects were approved by
Ethic Committee of the Institutes of Biomedical Sciences (IBS), Fudan Univer-
sity. Primers used for amplifying and sequencing IDH1 are described in
Supplemental Experimental Procedures. Tissue sections from glioma samples
were deparaffinized twice by xylene and then hydrated. Hydrogen peroxide
(0.6%) was used to eliminate endogenous peroxidase activity. The sections
were blocked with goat serum in TBS for 30min. Sections were then incubated
with either anti-endostatin antibody (Abcam) or anti-H3K79me2 antibody
(Abcam) at 1:500 dilution overnight at 4C. Secondary antibody was then
applied and incubated at 37C for 1 hr. Sections were developed with DAB
kit and stoppedwith water. To quantify the positive area of staining in samples,
five fields from each sample were randomly selected and microscopically
examined by a pathologist and a neurobiologist in a double-blind manner.
Images were captured using a charge-coupled device camera and analyzed
using Motic Images Advanced software (version 3.2, Motic China Group
Co. Ltd). Cells showing either cytoplasmic or nuclear signals (brown) were
counted as positive. The average positive area was calculated by dividing
the positively stained areas over total area.
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The atomic coordinates of the complex have been deposited in the Protein
Data Bank with accession number 3PUQ (CeKDM7A in complex with a-KG)
and 3PUR (CeKDM7A in complex with D-2-HG).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
doi:10.1016/j.ccr.2010.12.014.
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